VEA
RIGL icon

Virtus ETF Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Virtus ETF Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,027
Closed -$344K – 534
2025
Q4 		$344K Hold
8,027
– – 0.16% 156
2025
Q3 		$227K Hold
8,027
– – 0.13% 198
2025
Q2 		$150K Hold
8,027
– – 0.09% 238
2025
Q1 		$144K Buy
+8,027
New +$163K 0.09% 254
2021
Q4 		– Sell
-10,466
Closed -$380K – 394
2021
Q3 		$380K Sell
10,466
-960
-8% -$37.8K 0.17% 182
2021
Q2 		$496K Buy
11,426
+2,229
+24% +$84.2K 0.2% 154
2021
Q1 		$315K Buy
9,197
+161
+2% +$6.38K 0.13% 233
2020
Q4 		$316K Sell
9,036
-8,088
-47% -$234K 0.13% 197
2020
Q3 		$411K Sell
17,124
-2,334
-12% -$57.3K 0.22% 164
2020
Q2 		$356K Buy
19,458
+3,334
+21% +$60K 0.17% 260
2020
Q1 		$252K Sell
16,124
-2,350
-13% -$50K 0.1% 248
2019
Q4 		$395K Buy
+18,474
New +$380K 0.06% 261
2018
Q4 		– Sell
-23,402
Closed -$751K – 368
2018
Q3 		$751K Buy
23,402
+1,603
+7% +$48.1K 0.08% 69
2018
Q2 		$617K Buy
21,799
+511
+2% +$18.2K 0.55% 129
2018
Q1 		$754K Buy
21,288
+11,415
+116% +$457K 0.65% 84
2017
Q4 		$383K Sell
9,873
-2,766
-22% -$105K 0.48% 62
2017
Q3 		$321K Buy
12,639
+1,156
+10% +$28.1K 0.04% 128
2017
Q2 		$313K Buy
11,483
+243
+2% +$6.65K 0.05% 115
2017
Q1 		$372K Buy
11,240
+1,077
+11% +$27.4K 0.07% 119
2016
Q4 		$242K Buy
+10,163
New +$291K 0.07% 150

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus ETF Advisers's RIGL Position: Q1 2026 in Review

Virtus ETF Advisers sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 8,027 shares — an estimated $344K sold.

Virtus ETF Advisers first reported a position in RIGL in Q4 2016 and held it in 20 quarters. The position peaked at $754K in Q1 2018. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Virtus ETF Advisers reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Virtus ETF Advisers sold 8,027 Rigel Pharmaceuticals shares in Q1 2026, an estimated $344K.
  • Virtus ETF Advisers first reported a position in Rigel Pharmaceuticals in Q4 2016 and held it in 20 quarters.
  • Virtus ETF Advisers's Rigel Pharmaceuticals position peaked at $754K in Q1 2018.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.